Myeloma and Related Diseases Registry (MRDR)

Congratulations to Dr Joanne Tan, who recently published "The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population" in the British Journal of Haematology. DOI: 10.1111/bjh.18536

More information

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
5699

Patients accrued

3879

Patients with multiple myeloma

57

Number of approved sites

599

Biobank participants

Latest news

New MRDR publication
17 Nov 2022

Paper on the second revision of the International Staging System (R2-ISS) accepted for publication!

Read more
MRDR at 4th National Myeloma Workshop
17 Nov 2022

The MRDR was recently represented at the 4th National Myeloma Workshop.

Read more
MRDR Interest Group breakfast at Blood 2022
30 Sep 2022

Thank you to all attendees for contributing to a successful MRDR Interest Group breakfast at Blood 2022!

Read more
MRDR paper on early mortality in multiple myeloma accepted for publication
15 Jul 2022

Paper on on early mortality in multiple myeloma accepted for publication!

Read more

Participating organisations